Skip to main content

SOPRANO

02554903

SOPRANO

Associated Conditions

Pulmonary Hypertension

Principal Investigator

Sponsor

Actelion Pharmaceuticals

The purpose of this study is to evaluate the effect of macitentan 10 mg on pulmonary vascular resistance (PVR) as compared to placebo in subjects with pulmonary hypertension (PH) after left ventricular assist device (LVAD) implantation.

This study is currently enrolling.


Interested in participating?

Fill out the information below and we will reach out to you within two business days with more information on qualifications for this trial and how to participate.